Advertisement for orthosearch.org.uk
Results 1 - 1 of 1
Results per page:
Orthopaedic Proceedings
Vol. 98-B, Issue SUPP_23 | Pages 17 - 17
1 Dec 2016
Stravinskas M Horstmann PF Hettwer W Nilson M Tarasevicius S Petersen MM Lidgren L
Full Access

Aim

The demand for a synthetic bone substitute that can build bone and at the same time kill bacteria is high. The aim of this study was to compare the elution of gentamicin from a new synthetic bone substitute in vitro with the performance in clinical applications.

Method

Gentamicin release was measured from a synthetic bone graft substitute, comparing in vitro and clinical conditions:

elution in Ringers solution. The bone graft substitute contained 175mg gentamicin per 10mL. The material was introduced either as paste or as pre-set beads with a high or low surface areas, >100cm2 and 24cm2 respectively. The gentamycin release was measured by daily collection of samples.

elution in patients treated for trochanteric hip fractures(n=6) or uncemented hip revisions(n=5) 7,3±1,1mL of substitute was implanted and drainage was collected at 6h,12h,24h,30h,36h post-op. Blood serum was collected every hour for the first 6h and thereafter every 6h until 4 days post-op, urine – daily for the first 7 days post-op.

elution in patients treated after bone tumor resection(n=8), 12,1±5,5mL of substitute was implanted and both drainage and blood serum were collected daily until 2 days post-op.

Gentamicin concentrations were analyzed using antibody technique.